Anatoxin exposure and hepatitis C virus in advanced liver disease in a hepatitis C virus-endemic area in Taiwan

American Journal of Tropical Medicine and Hygiene

Volumn 77, Issue 4, 2007, Pages 747-752

  Chen, Chien Hung ^b   Wang, Mei Hui ^c   Wang, Jing Houng ^b   Hung, Chao Hung ^b   Hu, Tsung Hui ^b   Lee, Shui Cheng ^c   Tung, Hung Da ^d   Lee, Chuan Mo ^b   Changchien, Chi Sin ^b   Chen, Pao Fei ^b   Hsu, Mei Chin ^b   Lu, Sheng Nan ^a,b  

^a Department of Internal Medicine ^*  (Taiwan)

^b CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^c INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^d CHI MEI MEDICAL CENTER   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AFLATOXIN; AFLATOXIN ALBUMIN ADDUCT; AFLATOXIN B1; AFLATOXIN-ALBUMIN ADDUCT; ALBUMINOID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDEMIC DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; TAIWAN; BLOOD; CHEMICALLY INDUCED DISORDER; DISEASE COURSE; ENVIRONMENTAL EXPOSURE; IMMUNOLOGY; INFORMATION PROCESSING; MIDDLE AGED; VIROLOGY;

HEPATITIS C VIRUS;

AFLATOXIN B1; AFLATOXINS; AGED; ALBUMINS; DATA COLLECTION; DISEASE PROGRESSION; ENDEMIC DISEASES; ENVIRONMENTAL EXPOSURE; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; LIVER DISEASES; MALE; MIDDLE AGED; RISK FACTORS; TAIWAN;

EID: 38449092178     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2007.77.747     Document Type: Article

References (42)

1. Alter MJ, 1995. Epidemiology of hepatitis C in the West. Semin Liver Dis 15: 5-14.
2. Poynard T, Bedossa P, Opolon P, 1997. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet 349: 825-832.
3. Kiyosawa K, Sodeyama T, Tanaka E, Gibo Y, Yoshizawa K, Nakano Y, Furuta S, Akahane Y, Nishioka K, Purcell RH, 1990. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671-675.
4. Lee CM, Lu SN, Changchien CS, Yeh CT, Hsu TT, Tang JH, Wang JH, Lin DY, Chen CL, Chen WJ, 1999. Age, gender, and local geographic variations of viral etiology of hepatocellular carcinoma in a hyperendemic area for hepatitis B virus infection. Cancer 86: 1143-1150.
5. Niederau C, Lange S, Heintges T, Erhardt A, Buschkamp M, Hurter D, Nawrocki M, Kruska L, Hensel F, Petry W, Haussinger D, 1998. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 28: 1687-1695.
6. Takano S, Yokosuka O, Imazeki F, Tagawa M, Omata M, 1995. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology 21: 650-655.
7. Fattovich G, Stroffolini T, Zagni I, Donato F, 2004. Cirrhosis and hepatocellular carcinoma: incidence and factors related to development of hepatocellular carcinoma. Gastroenterology 127: S35-S50.
8. Lu SN, Su WW, Yang SS, Chang TT, Cheng KS, Wu JC, Lin HH, Wu SS, Lee CM, Changchien CS, Chen CJ, Sheu JC, Chen DS, Chen CH, 2006. Secular trends and geographic variations of hepatitis B virus and hepatitis C virus-associated hepatocellular carcinoma in Taiwan. Int J Cancer 119: 1946-1952.
9. Chen DS, Kuo GC, Sung JL, Lai MY, Sheu JC, Chen PJ, Yang PM, Hsu HM, Chang MH, Chen CJ, 1990. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. J Infect Dis 162: 817-822.
10. Wang JT, Wang TH, Sheu JC, Tsai SJ, Hsieh YS, Lin DT, Wang CY, Chen DS, 1993. Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction. Arch Pathol Lab Med 117: 152-156.
11. Lu SN, Chue PY, Chen HC, Wu MH, Chen IL, Huang JF, Wang JH, Peng CF, Shih CH, You SL, Lu CF, Chen CJ, Chang WY, 1997. Different viral aetiology of hepatocellular carcinoma between two hepatitis B and C endemic townships in Taiwan. J Gastroenterol Hepatol 12: 547-550.
12. Lu SN, Wang JH, Kuo YK, Kuo HL, Chen TM, Tung HD, Lee CM, Chen SC, 2002. Predicting the prevalence of antibody to hepatitis C virus (HCV) in a community by the prevalence of elevated levels of alanine aminotransferase: a method to identify areas endemic for HCV. Am J Trop Med Hyg 67: 145-150.
13. Tsai MC, Kee KM, Chen YD, Lin LC, Tsai LS, Chen HH, Lu SN, 2007. Excess mortality of hepatocellular carcinoma and morbidity of liver cirrhosis and hepatitis in HCV-endemic areas in an HBV-endemic country-geographic variations among 502 villages in southern Taiwan. J Gastroenterol Hepatol 22: 92-98.
14. Hatch MC, Chen CJ, Levin B, Ji BT, Yang GY, Hsu SW, Wang LW, Hsieh LL, Santella RM, 1993. Urinary aflatoxin levels, hepatitis B virus infection and hepatocellular carcinoma in Taiwan. Int J Cancer 54: 931-934.
15. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, Wang J, Wu Y, Liu G, Wu Y, Zhu Y, 1999. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology 30: 379-383.
16. Wang LY, Hatch M, Chen CJ, Levin B, You SL, Lu SN, Wu MH, Wu WP, Wang LW, Wang Q, Huang GT, Yang PM, Lee HS, Santella RM, 1996. Aflatoxin exposure and the risk of hepatocellular carcinoma in Taiwan. Int J Cancer 67: 620-625.
17. Chen CJ, Wang LY, Lu SN, Wu MH, You SL, Zhang YJ, Wang LW, Santella RM, 1996. Elevated aflatoxin exposure and increased risk of hepatocellular carcinoma. Hepatology 24: 38-42.
18. Yu MW, Lien JP, Chiu YH, Santella RM, Liaw YF, Chen CJ, 1997. Effect of aflatoxin metabolism and DNA adduct formation on hepatocellular carcinoma among chronic hepatitis B carriers in Taiwan. J Hepatol 27: 320-330.
19. Hifnawy MS, Mangoud AM, Eissa MH, Edin EN, Mostafa Y, Abouel-magd Y, Sabee EI, Amin I, Ismail A, Morsy TA, Mahrous S, Afefy AF, el-Shorbagy E, el-Sadawy M, Ragab H, Hassan MI, el-Hady G, Saber M, 2004. The role of aflatoxin-contaminated food materials and HCV in developing hepatocellular carcinoma in Al-Sharkia governorate, Egypt. J Egypt Soc Parasitol 34: 479-488.
20. Forrester LM, Neal GE, Judah DJ, Glancey MJ, Wolf CR, 1990. Evidence for involvement of multiple forms of cytochrome P450 in aflatoxin Bl metabolism in human liver. Proc Natl Acad Sci USA 87: 8306-8310.
21. Gallagher EP, Wienkers LC, Stapleton PL, Kunze KL, Eaton DL, 1994. Role of human microsomal and human complementary DNA-expressed cytochromes P4501A2 and P4503A4 in the bioactivation of aflatoxin B1. Cancer Res 54: 101-108.
22. Puisieux A. Lim S, Groopman J, Ozturk M, 1991. Selective targeting of p53 gene mutational hotspots in human cancers by etiologically defined carcinogen. Cancer Res 51: 6158-6189.
23. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC, 1991. Mutation hotspot in p53 gene in human hepatocellular carcinomas. Nature 350: 427-428.
24. Bressac B, Kew M, Wands J, Ozturk M, 1991. Selective G to T mutations of p53 gene in hepatocellular carcinoma from South Africa. Nature 350: 429-431.
25. Ozturk M, 1991. P53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 338: 1356-1359.
26. Colombo M, 1992. Hepatocellular carcinoma. J Hepatol 15: 225-236.
27. Ross RK, Yuan JM, Yu MC, Wogan GN, Qian GS, Tu JT, Groopman JD, Gao YT, Henderson BE, 1992. Urinary aflatoxin biomarkers and risk of hepatocellular carcinoma. Lancet 339: 943-946.
28. Qian GS, Ross RK, Yu MC, Yuan JM, Gao YT, Henderson BE, Wogan GN, Groopman JD, 1994. A follow-up study of urinary markers of aflatoxin exposure and liver cancer risk in Shanghai, People's Republic of China. Cancer Epidemol Biomarker Prev 3: 3-10.
29. Sheabar FZ, Groopman JD, Qian GS, Wogan GN, 1993. Quantitative analysis of aflatoxin-albumin adducts. Carcinogenesis 14: 1203-1208.
30. Wang JS, Qian GS, Zarba A, He X, Zhu YR, Zhang BC, Jacobson L, Gange SJ, Munoz A, Kensler TW, Groopman JD, 1996. Temporal patterns of aflatoxin-ablumin adducts in hepatitis B surface antigen-positive and antigen-negative residents of Daxin, Qidong County, People's Republic of China. Cancer Epidemol Biomarker Prev 5: 253-261.
31. Kawamura O, Lim JM, Okumura H, Kishimoto S, Chen G, Yu SZ, Ueno Y, 1996. Analysis of aflatoxin B1-human serum albumin adducts by a Sandwich Enzyme-Linked Immunosorbent Assay. Mycotoxins 43: 43-46.
32. Wang MH, Lee SC, Chiang TC, Farn SS, Fu YK, 2005. Assessment of aflatoxin-albumin analysis in serum by a competitive enzyme-linked immunosorbent assay. Clin Chem 51: A197.
33. Lu SN, Wang JH, Liu SL, Hung CH, Chen CH, Tung HD, Chen TM, Huang WS, Lee CM, Chen CC, Changchien CS, 2006. Thrombocytopenia as a surrogate of liver cirrhosis and a marker for identification of the high risk subjects of hepatocellular carcinoma. Cancer 107: 2212-2222.
34. Hung CH, Lu SN, Wang JH, Lee CM, Chen TM, Tung HD, Chen CH, Huang WS, Changchien CS, 2003. Correlation of ultrasonographic and pathologic diagnoses for hepatitis B and C related liver cirrhosis. J Gastroenterol 38: 153-157.
35. Gan LS, Skipper PL, Peng XC, Groopman JD, Chen JS, Wogan GN, Tannenbaum SR, 1988. Serum albumin adducts in the molecular epidemiology of aflatoxin carcinogenesis: correlation with aflatoxin B1 intake and urinary excretion of aflatoxin M1. Carcinogenesis 9: 1323-1325.
36. Wild CP, Hudson GJ, Sabbioni G, Chapot B, Hall AJ, Wogan GN, Whittle H, Montesano R, Groopman JD, 1992. Dietary intake of aflatoxins and the level of albumin-bound aflatoxin in peripheral blood in The Gambia, West Africa. Cancer Epidemiol Biomarkers Prev 1: 229-234.
37. Kirby GM, Batist G, Alpert L, Lamoureux E, Cameron RG, Alaoui-Jamali MA, 1996. Overexpression of chytochrome P-450 isoforms involved in aflatoxin B1 bioactivation in human liver with cirrhosis and hepatitis. Toxicol Pathol 2: 458-467.
38. Kirby GM, Chemin I, Montesano R, Chisari FV, Lang MA, Wild CP, 1994. Induction of specific cytochrome P450s involved in aflatoxin B1 metabolism in hepatitis B virus transgenic mice. Mol Carcinog 11: 74-80.
39. Gemechu-Hatewu M, Piatt KL, Oesch F, Hacker HJ, Bannasch P, Steinberg P, 1997. Metabolic activation of aflatoxin B1 to aflatoxin B1-8,9-epoxidein woodchucks undergoing chronic active hepatitis. Int J Cancer 73: 587-591.
40. Turner PC, Mendy M, Whittle H, Fortuin M, Hall AJ, Wild CP, 2000. Hepatitis B infection and aflatoxin biomarker levels in Gambian children. Trop Med int Health 5: 837-841.
41. De Flora S, Romano M, Basso C, Serra D, Astergo M, Picciotto A, 1985. Metabolic activation of hepatocarcinogens in chronic hepatitis B. Cancer Res 47: 4052-4058.
42. Sun CA, Wu DM, Wang LY, Chen CJ, You SL, Santella RM, 2002. Determinants of formation of aflatoxin-albumin adducts: a seven-township study in Taiwan. Br J Cancer 87: 966-970.